-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that CMB International released a research report stating that the target price of China Biopharmaceuticals (01177.HK) was raised by 3.4% from HK$8.7 to HK$9, maintaining the “buy” rating. Considering that the company continues to fulfill BD transactions in 2026, the bank raised its forecast. Revenue is expected to increase 11.5%, 13.2% and 10.4% year-on-year in 2026, 2027 and 2028, respectively, and adjusted net profit to mother will increase by 12.5%, 19.4%, and 9.9%, respectively.

Zhitongcaijing·11/17/2026 03:09:04
Listen to the news
The Zhitong Finance App learned that CMB International released a research report stating that the target price of China Biopharmaceuticals (01177.HK) was raised by 3.4% from HK$8.7 to HK$9, maintaining the “buy” rating. Considering that the company continues to fulfill BD transactions in 2026, the bank raised its forecast. Revenue is expected to increase 11.5%, 13.2% and 10.4% year-on-year in 2026, 2027 and 2028, respectively, and adjusted net profit to mother will increase by 12.5%, 19.4%, and 9.9%, respectively.